Company news

Plus Therapeutics, Inc. news in 2026

Plus Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cerenome Launches as an Integrated CNS Oncology Company

July 31, 2026

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

July 28, 2026

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

July 21, 2026

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

July 16, 2026

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

July 14, 2026

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

June 30, 2026

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

June 25, 2026

Plus Therapeutics to Provide Business Update Call on June 30, 2026

June 23, 2026

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

June 3, 2026

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

May 26, 2026

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

May 15, 2026

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 8, 2026

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

May 7, 2026

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

April 27, 2026

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

April 23, 2026

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

April 21, 2026

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

April 14, 2026

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

April 8, 2026

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

April 7, 2026

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

April 6, 2026

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

April 1, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

March 30, 2026

Plus Therapeutics Announces Reverse Stock Split

March 30, 2026

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

March 25, 2026

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

March 18, 2026

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

March 11, 2026

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

February 25, 2026

Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

January 22, 2026

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9: 00 A.M. ET

January 21, 2026

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

January 14, 2026

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

January 8, 2026

Decks in 2026